FDA Approves Supplemental New Drug Application for Gilead Sciences Treatment
March 19 2020 - 3:48PM
Dow Jones News
By Allison Prang
A supplemental new drug application for a hepatitis C treatment
from Gilead Sciences Inc. was approved by the U.S. Food and Drug
Administration, Gilead said on Thursday.
Epclusa was approved for people who either weigh at least 17
kilograms or are at least 6 years old, Gilead said.
Gilead said the agency's approval is based on Phase II clinical
trial data.
A child's dose of the treatment depends on how much they weigh
and their liver's functioning, the company said.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
March 19, 2020 15:33 ET (19:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024